Bioequivalence and Bioavailability Forum • 🇦🇹 AGES

🇦🇹 AGES [Regulatives / Guidelines]

posted by Helmut – Vienna, Austria, 2024-07-24 13:16 (303 d 01:02 ago) – Posting: # 24097
Views: 2,756

Hi Mittyri,

oh dear!

The presence of period, sequence, and treatment effects were evaluated.

Why the heck?

For AUC_0-t, a significant treatment effect was observed for ASA (p = 0.0221).

So what?

The lower and upper limit of the CI was below 100% …

A consequence of p < 0.05.

… but within the lower limit of the acceptance range of 80.00[%]

Again: So what?
Similar nonsense for SA.

—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz

[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

FDC with ascorbic acid qualityassurance 2024-07-23 08:08 [Regulatives / Guidelines]
- FDC with ascorbic acid Ohlbe 2024-07-23 09:55
  - FDC with ascorbic acid qualityassurance 2024-07-23 10:13
    - Placebo? Helmut 2024-07-23 12:39
      - Placebo? mittyri 2024-07-23 14:54
        
        🇦🇹 AGESHelmut 2024-07-24 11:16
      - Placebo? qualityassurance 2024-07-24 11:37
        
        Sorry – wrong addressee Helmut 2024-07-24 13:31
        
        lucky mittyri 2024-07-24 16:01

Admin contact
23,424 posts in 4,927 threads, 1,679 registered users;
40 visitors (0 registered, 40 guests [including 21 identified bots]).
Forum time: 14:18 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body. Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz